EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

Rana R McKay iD, Sumanta Pal, Wanling Xie iD, David Aggen iD, Laurence Albiges iD, Andrea Apolo iD, Michael B Atkins iD, Rick Bangs iD, Kathryn E Beckermann iD, Joaquim Bellmunt iD, Stephanie A Berg iD, Mehmet A Bilen iD und 42 weitere

CA: A Cancer Journal for Clinicians · 2026-01 · 76 (1)

DOI: 10.3322/caac.70052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 13.12.2025. Verfasst von Rana R McKay und 53 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Urology, and Radiation Medicine and Applied Sciences, University of California-San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence‐based expert consensus recommendations for optimal management. A multidisciplinary panel of 51 experts participated in a modified Delphi process addressing questions developed through iterative consensus‐building covering RCC and UTC management. Voting occurred before and after the conference, and analyses focused on postmeeting responses. Consensus was defined as ≥75% agreement, with strong consensus as >90%. Strong consensus was found on the use of adjuvant pembrolizumab for higher risk RCC (pathologic T2 [pT2], grade 4; pT3–pT4, any grade; pTXN1; or fully resected metastatic disease) and on neoadjuvant therapy before cystectomy for localized UTC. There was strong consensus on the use of enfortumab vedotin plus pembrolizumab as frontline therapy for metastatic UTC and the use of platinum‐based chemotherapy postprogression in biomarker‐negative UTC. For RCC, there was consensus on the role of single‐agent vascular endothelial growth factor receptor–tyrosine kinase inhibitor therapy after progression on frontline immune checkpoint inhibitor/vascular endothelial growth factor receptor–tyrosine kinase inhibitor therapy or dual immune checkpoint inhibitor therapy. However, there was a lack of consensus on other critical areas in the management of RCC and UTC. The 2025 Advanced Urologic Cancer Consensus Conference provides evidence‐informed guidance for complex clinical scenarios while identifying critical research priorities. The group recognizes that the lack of consensus across multiple areas highlights the need for improved patient selection and prospective studies enabling optimal combination and sequencing approaches. This iterative annual process will address evolving treatment paradigms to optimize outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsUrologic NeoplasmsHumansAntibodies, Monoclonal, HumanizedNeoadjuvant Therapy

Stichwörter der Autor:innen

Delphi processexpert panel consensusrenal cell carcinomatreatment optimizationurothelial carcinoma

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Department of Medicine, Urology, and Radiation Medicine and Applied Sciences, University of California-San Diego, La Jolla, California, USA.
  • Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Rana R McKay, Wanling Xie, David Aggen, Laurence Albiges, Andrea Apolo, Michael B Atkins, Rick Bangs, Kathryn E Beckermann, Joaquim Bellmunt, Stephanie A Berg, Mehmet A Bilen, David Braun, Maria I Carlo, Jason Efstathiou, Matthew Galsky, Petros Grivas, Naomi Haas, A Ari Hakimi, Hans Hammers, Michelle Hirsch, Eric Jonasch, Vadim S Koshkin, Roger Li, Surena Matin, Benjamin Maughan, David F McDermott, Bradley McGregor, Joshua Meeks, Matthew Milowsky, Robert Motzer, Andrea Necchi, Sima Porten, Thomas Powles, Brian Rini, Arlene Siefker-Radtke, Guru Sonpavde, S Srikala Sridhar, Chad Tang, Michiel S Van Der Heijden, Wenxin Xu, Jonathan Rosenberg, Toni K Choueiri

Förderung

  • NCI NIH HHS

Zitieren

APA

McKay, R. R., Pal, S., Xie, W., Aggen, D., Albiges, L., Apolo, A., Atkins, M. B., Bangs, R., Beckermann, K. E., Bellmunt, J., Berg, S. A., Bilen, M. A., Braun, D., Carlo, M. I., Efstathiou, J., Galsky, M., Grivas, P., Gupta, S., Haas, N., …, & Choueiri, T. K. (2026). Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA: A Cancer Journal for Clinicians, 76(1). https://doi.org/10.3322/caac.70052

Vancouver

McKay RR, Pal S, Xie W, Aggen D, Albiges L, Apolo A, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA: A Cancer Journal for Clinicians. 2026;76(1). doi:10.3322/caac.70052

BibTeX
@article{McKay2026,
  author = {McKay, Rana R and Pal, Sumanta and Xie, Wanling and Aggen, David and Albiges, Laurence and Apolo, Andrea and Atkins, Michael B and Bangs, Rick and Beckermann, Kathryn E and Bellmunt, Joaquim and Berg, Stephanie A and Bilen, Mehmet A and Braun, David and Carlo, Maria I and Efstathiou, Jason and Galsky, Matthew and Grivas, Petros and Gupta, Shilpa and Haas, Naomi and Hakimi, A Ari and Hammers, Hans and Heng, Daniel Y C and Hirsch, Michelle and Iyer, Gopakumar and Jonasch, Eric and Koshkin, Vadim S and Kryvenko, Oleksandr and Lewis, Bryan and Li, Roger and Matin, Surena and Maughan, Benjamin and McDermott, David F and McGregor, Bradley and Meeks, Joshua and Milowsky, Matthew and Motzer, Robert and Necchi, Andrea and Petrylak, Dan and Porten, Sima and Powles, Thomas and Rini, Brian and Shuch, Brian and Siefker-Radtke, Arlene and Sonpavde, Guru and Sridhar, S Srikala and Suarez, Cristina and Tang, Chad and Tripathi, Abhishek and Van Der Heijden, Michiel S and Voss, Martin and Xu, Wenxin and Zhang, Tian and Rosenberg, Jonathan and Choueiri, Toni K},
  title = {Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2026},
  volume = {76},
  number = {1},
  doi = {10.3322/caac.70052}
}
Kostenlos starten →